{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T14:58:31Z","timestamp":1790002711077,"version":"4.0.1"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,2,16]],"date-time":"2018-02-16T00:00:00Z","timestamp":1518739200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s00392-018-1202-x","type":"journal-article","created":{"date-parts":[[2018,2,16]],"date-time":"2018-02-16T08:54:54Z","timestamp":1518771294000},"page":"271-280","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Cardio-oncology: conflicting priorities of anticancer treatment and cardiovascular outcome"],"prefix":"10.1007","volume":"107","author":[{"given":"Lisa M.","family":"Tilemann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus B.","family":"Heckmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo A.","family":"Katus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenz H.","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver J.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,16]]},"reference":[{"issue":"10","key":"1202_CR1","doi-asserted-by":"publisher","first-page":"161","DOI":"10.3238\/arztebl.2014.0161","volume":"111","author":"A Schlitt","year":"2014","unstructured":"Schlitt A, Jordan K, Vordermark D, Schwamborn J, Langer T, Thomssen C (2014) Cardiotoxicity and oncological treatments. Dtsch Arztebl Int 111(10):161\u2013168. \n                    https:\/\/doi.org\/10.3238\/arztebl.2014.0161","journal-title":"Dtsch Arztebl Int"},{"issue":"1","key":"1202_CR2","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.lungcan.2015.01.006","volume":"88","author":"J Kravchenko","year":"2015","unstructured":"Kravchenko J, Berry M, Arbeev K, Kim Lyerly H, Yashin A, Akushevich I (2015) Cardiovascular comorbidities and survival of lung cancer patients: medicare data based analysis. Lung Cancer 88(1):85\u201393. \n                    https:\/\/doi.org\/10.1016\/j.lungcan.2015.01.006","journal-title":"Lung Cancer"},{"issue":"19","key":"1202_CR3","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.1200\/JCO.2007.14.1242","volume":"26","author":"DL Hershman","year":"2008","unstructured":"Hershman DL, McBride RB, Eisenberger A, Tsai WY, Grann VR, Jacobson JS (2008) Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin\u2019s lymphoma. J Clin Oncol 26(19):3159\u20133165. \n                    https:\/\/doi.org\/10.1200\/JCO.2007.14.1242","journal-title":"J Clin Oncol"},{"issue":"2","key":"1202_CR4","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s12012-007-0024-2","volume":"7","author":"S Deng","year":"2007","unstructured":"Deng S, Wojnowski L (2007) Genotyping the risk of anthracycline-induced cardiotoxicity. Cardiovasc Toxicol 7(2):129\u2013134. \n                    https:\/\/doi.org\/10.1007\/s12012-007-0024-2","journal-title":"Cardiovasc Toxicol"},{"issue":"10","key":"1202_CR5","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1158\/1055-9965.EPI-11-0659","volume":"20","author":"S Bhatia","year":"2011","unstructured":"Bhatia S (2011) Role of genetic susceptibility in development of treatment-related adverse outcomes in cancer survivors. Cancer Epidemiol Biomark Prev 20(10):2048\u20132067. \n                    https:\/\/doi.org\/10.1158\/1055-9965.EPI-11-0659","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"13","key":"1202_CR6","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1016\/j.jacc.2014.07.948","volume":"64","author":"L Cramer","year":"2014","unstructured":"Cramer L, Hildebrandt B, Kung T, Wichmann K, Springer J, Doehner W, Sandek A, Valentova M, Stojakovic T, Scharnagl H, Riess H, Anker SD, von Haehling S (2014) Cardiovascular function and predictors of exercise capacity in patients with colorectal cancer. J Am Coll Cardiol 64(13):1310\u20131319. \n                    https:\/\/doi.org\/10.1016\/j.jacc.2014.07.948","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"1202_CR7","doi-asserted-by":"publisher","first-page":"H466","DOI":"10.1152\/ajpheart.00720.2015","volume":"310","author":"KT Murphy","year":"2016","unstructured":"Murphy KT (2016) The pathogenesis and treatment of cardiac atrophy in cancer cachexia. Am J Physiol Heart Circ Physiol 310(4):H466\u2013H477. \n                    https:\/\/doi.org\/10.1152\/ajpheart.00720.2015","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"1","key":"1202_CR8","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ejcsup.2014.03.002","volume":"12","author":"BM Aleman","year":"2014","unstructured":"Aleman BM, Moser EC, Nuver J, Suter TM, Maraldo MV, Specht L, Vrieling C, Darby SC (2014) Cardiovascular disease after cancer therapy. EJC Suppl 12(1):18\u201328. \n                    https:\/\/doi.org\/10.1016\/j.ejcsup.2014.03.002","journal-title":"EJC Suppl"},{"issue":"1","key":"1202_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1634\/theoncologist.2008-0137","volume":"14","author":"M Martin","year":"2009","unstructured":"Martin M, Esteva FJ, Alba E, Khandheria B, Perez-Isla L, Garcia-Saenz JA, Marquez A, Sengupta P, Zamorano J (2009) Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations. Oncologist 14(1):1\u201311. \n                    https:\/\/doi.org\/10.1634\/theoncologist.2008-0137","journal-title":"Oncologist"},{"key":"1202_CR10","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw211","author":"JL Zamorano","year":"2016","unstructured":"Zamorano JL, Lancellotti P, Rodriguez Munoz D, Aboyans V, Asteggiano R, Galderisi M, Habib G, Lenihan DJ, Lip GY, Lyon AR, Lopez Fernandez T, Mohty D, Piepoli MF, Tamargo J, Torbicki A, Suter TM, Authors\/Task Force M, Guidelines ESCCfP (2016) 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehw211","journal-title":"Eur Heart J"},{"issue":"12","key":"1202_CR11","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/j.recesp.2016.10.014","volume":"69","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P (2016) 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Rev Esp Cardiol (Engl Ed) 69(12):1167. \n                    https:\/\/doi.org\/10.1016\/j.rec.2016.11.005","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"issue":"25 Pt A","key":"1202_CR12","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1016\/j.jacc.2014.01.073","volume":"63","author":"P Thavendiranathan","year":"2014","unstructured":"Thavendiranathan P, Poulin F, Lim KD, Plana JC, Woo A, Marwick TH (2014) Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J Am Coll Cardiol 63(25 Pt A):2751\u20132768. \n                    https:\/\/doi.org\/10.1016\/j.jacc.2014.01.073","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"1202_CR13","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1200\/JCO.2005.05.827","volume":"23","author":"MS Ewer","year":"2005","unstructured":"Ewer MS, Lippman SM (2005) Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 23(13):2900\u20132902. \n                    https:\/\/doi.org\/10.1200\/JCO.2005.05.827","journal-title":"J Clin Oncol"},{"issue":"7","key":"1202_CR14","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1002\/cncr.10854","volume":"95","author":"DL Keefe","year":"2002","unstructured":"Keefe DL (2002) Trastuzumab-associated cardiotoxicity. Cancer 95(7):1592\u20131600. \n                    https:\/\/doi.org\/10.1002\/cncr.10854","journal-title":"Cancer"},{"issue":"10","key":"1202_CR15","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/nrcardio.2010.121","volume":"7","author":"MS Ewer","year":"2010","unstructured":"Ewer MS, Ewer SM (2010) Cardiotoxicity of anticancer treatments: What the cardiologist needs to know. Nat Rev Cardiol 7(10):564\u2013575. \n                    https:\/\/doi.org\/10.1038\/nrcardio.2010.121","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"1202_CR16","doi-asserted-by":"publisher","first-page":"232470961348034","DOI":"10.1177\/2324709613480346","volume":"1","author":"S Dhesi","year":"2013","unstructured":"Dhesi S, Chu MP, Blevins G, Paterson I, Larratt L, Oudit GY, Kim DH (2013) Cyclophosphamide-induced cardiomyopathy: a case report, review, and recommendations for management. J Investig Med High Impact Case Rep 1(1):2324709613480346. \n                    https:\/\/doi.org\/10.1177\/2324709613480346","journal-title":"J Investig Med High Impact Case Rep"},{"issue":"5","key":"1202_CR17","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/j.1365-2141.2005.05759.x","volume":"131","author":"KA Wouters","year":"2005","unstructured":"Wouters KA, Kremer LC, Miller TL, Herman EH, Lipshultz SE (2005) Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br J Haematol 131(5):561\u2013578. \n                    https:\/\/doi.org\/10.1111\/j.1365-2141.2005.05759.x","journal-title":"Br J Haematol"},{"issue":"2","key":"1202_CR18","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1096\/fasebj.13.2.199","volume":"13","author":"G Minotti","year":"1999","unstructured":"Minotti G, Cairo G, Monti E (1999) Role of iron in anthracycline cardiotoxicity: new tunes for an old song? FASEB J 13(2):199\u2013212","journal-title":"FASEB J"},{"issue":"24","key":"1202_CR19","doi-asserted-by":"publisher","first-page":"3754","DOI":"10.1161\/CIRCULATIONAHA.105.576850","volume":"112","author":"L Wojnowski","year":"2005","unstructured":"Wojnowski L, Kulle B, Schirmer M, Schluter G, Schmidt A, Rosenberger A, Vonhof S, Bickeboller H, Toliat MR, Suk EK, Tzvetkov M, Kruger A, Seifert S, Kloess M, Hahn H, Loeffler M, Nurnberg P, Pfreundschuh M, Trumper L, Brockmoller J, Hasenfuss G (2005) NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 112(24):3754\u20133762. \n                    https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.105.576850","journal-title":"Circulation"},{"issue":"11","key":"1202_CR20","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1002\/cncr.11407","volume":"97","author":"SM Swain","year":"2003","unstructured":"Swain SM, Whaley FS, Ewer MS (2003) Congestive heart failure in patients treated with doxorubicin\u2014a retrospective analysis of three trials. Cancer 97(11):2869\u20132879. \n                    https:\/\/doi.org\/10.1002\/cncr.11407","journal-title":"Cancer"},{"issue":"1","key":"1202_CR21","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1200\/JCO.2008.17.2627","volume":"27","author":"ML Hensley","year":"2009","unstructured":"Hensley ML, Hagerty KL, Kewalramani T, Green DM, Meropol NJ, Wasserman TH, Cohen GI, Emami B, Gradishar WJ, Mitchell RB, Thigpen JT, Trotti A, 3rd, von Hoff D, Schuchter LM (2009) American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol 27 (1):127\u2013145. \n                    https:\/\/doi.org\/10.1200\/JCO.2008.17.2627","journal-title":"J Clin Oncol"},{"issue":"22","key":"1202_CR22","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","volume":"131","author":"D Cardinale","year":"2015","unstructured":"Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, Civelli M, Lamantia G, Colombo N, Curigliano G, Fiorentini C, Cipolla CM (2015) Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 131(22):1981\u20131988. \n                    https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.114.013777","journal-title":"Circulation"},{"issue":"11","key":"1202_CR23","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1002\/ajh.21840","volume":"85","author":"P Georgakopoulos","year":"2010","unstructured":"Georgakopoulos P, Roussou P, Matsakas E, Karavidas A, Anagnostopoulos N, Marinakis T, Galanopoulos A, Georgiakodis F, Zimeras S, Kyriakidis M, Ahimastos A (2010) Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: a prospective, parallel-group, randomized, controlled study with 36-month follow-up. Am J Hematol 85(11):894\u2013896. \n                    https:\/\/doi.org\/10.1002\/ajh.21840","journal-title":"Am J Hematol"},{"issue":"23","key":"1202_CR24","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1016\/j.jacc.2013.02.072","volume":"61","author":"X Bosch","year":"2013","unstructured":"Bosch X, Rovira M, Sitges M, Domenech A, Ortiz-Perez JT, de Caralt TM, Morales-Ruiz M, Perea RJ, Monzo M, Esteve J (2013) Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J Am Coll Cardiol 61(23):2355\u20132362. \n                    https:\/\/doi.org\/10.1016\/j.jacc.2013.02.072","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"1202_CR25","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/2193-1801-2-198","volume":"2","author":"M Dessi","year":"2013","unstructured":"Dessi M, Madeddu C, Piras A, Cadeddu C, Antoni G, Mercuro G, Mantovani G (2013) Long-term, up to 18 months, protective effects of the angiotensin II receptor blocker telmisartan on Epirubin-induced inflammation and oxidative stress assessed by serial strain rate. Springerplus 2(1):198. \n                    https:\/\/doi.org\/10.1186\/2193-1801-2-198","journal-title":"Springerplus"},{"issue":"1081","key":"1202_CR26","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1136\/postgradmedj-2015-133535","volume":"91","author":"S Yun","year":"2015","unstructured":"Yun S, Vincelette ND, Abraham I (2015) Cardioprotective role of beta-blockers and angiotensin antagonists in early-onset anthracyclines-induced cardiotoxicity in adult patients: a systematic review and meta-analysis. Postgrad Med J 91(1081):627\u2013633. \n                    https:\/\/doi.org\/10.1136\/postgradmedj-2015-133535","journal-title":"Postgrad Med J"},{"key":"1202_CR27","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw022","author":"G Gulati","year":"2016","unstructured":"Gulati G, Heck SL, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, Gravdehaug B, von Knobelsdorff-Brenkenhoff F, Bratland A, Storas TH, Hagve TA, Rosjo H, Steine K, Geisler J, Omland T (2016) Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2\u2009\u00d7\u20092 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehw022","journal-title":"Eur Heart J"},{"issue":"6","key":"1202_CR28","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1001\/archinte.160.6.809","volume":"160","author":"JA Heit","year":"2000","unstructured":"Heit JA, Silverstein MD, Mohr DN, Petterson TM, O\u2019Fallon WM, Melton LJ 3rd (2000) Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 160 (6):809\u2013815","journal-title":"Arch Intern Med"},{"key":"1202_CR29","unstructured":"S2-Leitlinie: Diagnostik und Therapie der Venenthrombose und der Lungenembolie (2015)"},{"issue":"3","key":"1202_CR30","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1200\/JCO.2005.03.8877","volume":"24","author":"AA Khorana","year":"2006","unstructured":"Khorana AA, Francis CW, Culakova E, Fisher RI, Kuderer NM, Lyman GH (2006) Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol 24(3):484\u2013490. \n                    https:\/\/doi.org\/10.1200\/JCO.2005.03.8877","journal-title":"J Clin Oncol"},{"issue":"2","key":"1202_CR31","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1093\/annonc\/mdj068","volume":"17","author":"K Kroger","year":"2006","unstructured":"Kroger K, Weiland D, Ose C, Neumann N, Weiss S, Hirsch C, Urbanski K, Seeber S, Scheulen ME (2006) Risk factors for venous thromboembolic events in cancer patients. Ann Oncol 17(2):297\u2013303. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdj068","journal-title":"Ann Oncol"},{"issue":"6","key":"1202_CR32","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1001\/jama.293.6.715","volume":"293","author":"JW Blom","year":"2005","unstructured":"Blom JW, Doggen CJ, Osanto S, Rosendaal FR (2005) Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293(6):715\u2013722. \n                    https:\/\/doi.org\/10.1001\/jama.293.6.715","journal-title":"JAMA"},{"issue":"12","key":"1202_CR33","doi-asserted-by":"publisher","first-page":"2822","DOI":"10.1002\/cncr.21496","volume":"104","author":"AA Khorana","year":"2005","unstructured":"Khorana AA, Francis CW, Culakova E, Lyman GH (2005) Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer 104(12):2822\u20132829. \n                    https:\/\/doi.org\/10.1002\/cncr.21496","journal-title":"Cancer"},{"issue":"4","key":"1202_CR34","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1001\/archinte.166.4.458","volume":"166","author":"HK Chew","year":"2006","unstructured":"Chew HK, Wun T, Harvey D, Zhou H, White RH (2006) Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 166(4):458\u2013464. \n                    https:\/\/doi.org\/10.1001\/archinte.166.4.458","journal-title":"Arch Intern Med"},{"issue":"13","key":"1202_CR35","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1056\/NEJMoa012385","volume":"346","author":"D Bergqvist","year":"2002","unstructured":"Bergqvist D, Agnelli G, Cohen AT, Eldor A, Nilsson PE, Le Moigne-Amrani A, Dietrich-Neto F, Investigators EI (2002) Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 346(13):975\u2013980. \n                    https:\/\/doi.org\/10.1056\/NEJMoa012385","journal-title":"N Engl J Med"},{"issue":"7","key":"1202_CR36","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1093\/annonc\/mdr592","volume":"23","author":"F Petrelli","year":"2012","unstructured":"Petrelli F, Cabiddu M, Borgonovo K, Barni S (2012) Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials. Ann Oncol 23(7):1672\u20131679. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdr592","journal-title":"Ann Oncol"},{"issue":"13","key":"1202_CR37","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1200\/JCO.2009.27.2757","volume":"28","author":"TK Choueiri","year":"2010","unstructured":"Choueiri TK, Schutz FA, Je Y, Rosenberg JE, Bellmunt J (2010) Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol 28(13):2280\u20132285. \n                    https:\/\/doi.org\/10.1200\/JCO.2009.27.2757","journal-title":"J Clin Oncol"},{"issue":"19","key":"1202_CR38","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1001\/jama.2008.656","volume":"300","author":"SR Nalluri","year":"2008","unstructured":"Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S (2008) Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 300(19):2277\u20132285. \n                    https:\/\/doi.org\/10.1001\/jama.2008.656","journal-title":"JAMA"},{"issue":"6","key":"1202_CR39","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1111\/j.1365-2141.2005.05529.x","volume":"129","author":"A Cortelezzi","year":"2005","unstructured":"Cortelezzi A, Moia M, Falanga A, Pogliani EM, Agnelli G, Bonizzoni E, Gussoni G, Barbui T, Mannucci PM, Group CS (2005) Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: a prospective multicentre study. Br J Haematol 129(6):811\u2013817. \n                    https:\/\/doi.org\/10.1111\/j.1365-2141.2005.05529.x","journal-title":"Br J Haematol"},{"issue":"25","key":"1202_CR40","doi-asserted-by":"publisher","first-page":"3466","DOI":"10.1200\/JCO.2011.35.5669","volume":"29","author":"RA Moore","year":"2011","unstructured":"Moore RA, Adel N, Riedel E, Bhutani M, Feldman DR, Tabbara NE, Soff G, Parameswaran R, Hassoun H (2011) High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol 29(25):3466\u20133473. \n                    https:\/\/doi.org\/10.1200\/JCO.2011.35.5669","journal-title":"J Clin Oncol"},{"issue":"34","key":"1202_CR41","doi-asserted-by":"publisher","first-page":"5490","DOI":"10.1200\/JCO.2007.14.1283","volume":"25","author":"GH Lyman","year":"2007","unstructured":"Lyman GH, Khorana AA, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M, Kakkar A, Kuderer NM, Levine MN, Liebman H, Mendelson D, Raskob G, Somerfield MR, Thodiyil P, Trent D, Francis CW, American Society of Clinical O (2007) American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25 (34):5490\u20135505. \n                    https:\/\/doi.org\/10.1200\/JCO.2007.14.1283","journal-title":"J Clin Oncol"},{"issue":"2","key":"1202_CR42","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1177\/1076029611433769","volume":"18","author":"SK Haas","year":"2012","unstructured":"Haas SK, Freund M, Heigener D, Heilmann L, Kemkes-Matthes B, von Tempelhoff GF, Melzer N, Kakkar AK, Investigators T (2012) Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III\/IV lung cancer. Clin Appl Thromb Hemost 18(2):159\u2013165. \n                    https:\/\/doi.org\/10.1177\/1076029611433769","journal-title":"Clin Appl Thromb Hemost"},{"issue":"21","key":"1202_CR43","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1001\/jama.296.21.2558-c","volume":"296","author":"CL Bennett","year":"2006","unstructured":"Bennett CL, Angelotta C, Yarnold PR, Evens AM, Zonder JA, Raisch DW, Richardson P (2006) Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. JAMA 296(21):2558\u20132560. \n                    https:\/\/doi.org\/10.1001\/jama.296.21.2558-c","journal-title":"JAMA"},{"issue":"5","key":"1202_CR44","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1182\/blood.V98.5.1614","volume":"98","author":"M Zangari","year":"2001","unstructured":"Zangari M, Anaissie E, Barlogie B, Badros A, Desikan R, Gopal AV, Morris C, Toor A, Siegel E, Fink L, Tricot G (2001) Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 98(5):1614\u20131615","journal-title":"Blood"},{"issue":"5","key":"1202_CR45","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1634\/theoncologist.12-5-518","volume":"12","author":"K el-Shami","year":"2007","unstructured":"el-Shami K, Griffiths E, Streiff M (2007) Nonbacterial thrombotic endocarditis in cancer patients: pathogenesis, diagnosis, and treatment. Oncologist 12(5):518\u2013523. \n                    https:\/\/doi.org\/10.1634\/theoncologist.12-5-518","journal-title":"Oncologist"},{"issue":"5","key":"1202_CR46","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1161\/01.STR.0000015029.91577.36","volume":"33","author":"AB Singhal","year":"2002","unstructured":"Singhal AB, Topcuoglu MA, Buonanno FS (2002) Acute ischemic stroke patterns in infective and nonbacterial thrombotic endocarditis: a diffusion-weighted magnetic resonance imaging study. Stroke 33(5):1267\u20131273","journal-title":"Stroke"},{"issue":"6","key":"1202_CR47","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1001\/archneur.1974.00490420056006","volume":"31","author":"TJ Reagan","year":"1974","unstructured":"Reagan TJ, Okazaki H (1974) The thrombotic syndrome associated with carcinoma. A clinical and neuropathologic study. Arch Neurol 31(6):390\u2013395","journal-title":"Arch Neurol"},{"issue":"4","key":"1202_CR48","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/0002-9343(87)90908-9","volume":"83","author":"LR Rogers","year":"1987","unstructured":"Rogers LR, Cho ES, Kempin S, Posner JB (1987) Cerebral infarction from non-bacterial thrombotic endocarditis. Clinical and pathological study including the effects of anticoagulation. Am J Med 83(4):746\u2013756","journal-title":"Am J Med"},{"issue":"3","key":"1202_CR49","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/0002-8703(87)90719-8","volume":"113","author":"JA Lopez","year":"1987","unstructured":"Lopez JA, Ross RS, Fishbein MC, Siegel RJ (1987) Nonbacterial thrombotic endocarditis: a review. Am Heart J 113(3):773\u2013784","journal-title":"Am Heart J"},{"issue":"44","key":"1202_CR50","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.1093\/eurheartj\/ehv319","volume":"36","author":"G Habib","year":"2015","unstructured":"Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta JP, Del Zotti F, Dulgheru R, El Khoury G, Erba PA, Iung B, Miro JM, Mulder BJ, Plonska-Gosciniak E, Price S, Roos-Hesselink J, Snygg-Martin U, Thuny F, Tornos Mas P, Vilacosta I, Zamorano JL, Document R, Erol C, Nihoyannopoulos P, Aboyans V, Agewall S, Athanassopoulos G, Aytekin S, Benzer W, Bueno H, Broekhuizen L, Carerj S, Cosyns B, De Backer J, De Bonis M, Dimopoulos K, Donal E, Drexel H, Flachskampf FA, Hall R, Halvorsen S, Hoen B, Kirchhof P, Lainscak M, Leite-Moreira AF, Lip GY, Mestres CA, Piepoli MF, Punjabi PP, Rapezzi C, Rosenhek R, Siebens K, Tamargo J, Walker DM (2015) 2015 ESC guidelines for the management of infective endocarditis: the task force for the management of infective endocarditis of the european society of cardiology (ESC). Endorsed by: European association for cardio-thoracic surgery (EACTS), the European association of nuclear medicine (EANM). Eur Heart J 36(44):3075\u20133128. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehv319","journal-title":"Eur Heart J"},{"issue":"1","key":"1202_CR51","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.amjmed.2012.07.026","volume":"126","author":"RW Thomsen","year":"2013","unstructured":"Thomsen RW, Farkas DK, Friis S, Svaerke C, Ording AG, Norgaard M, Sorensen HT (2013) Endocarditis and risk of cancer: a Danish nationwide cohort study. Am J Med 126(1):58\u201367. \n                    https:\/\/doi.org\/10.1016\/j.amjmed.2012.07.026","journal-title":"Am J Med"},{"issue":"13","key":"1202_CR52","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1002\/cncr.28653","volume":"120","author":"C Shen","year":"2014","unstructured":"Shen C, Shih YC, Xu Y, Yao JC (2014) Octreotide long-acting repeatable use among elderly patients with carcinoid syndrome and survival outcomes: a population-based analysis. Cancer 120(13):2039\u20132049. \n                    https:\/\/doi.org\/10.1002\/cncr.28653","journal-title":"Cancer"},{"issue":"20","key":"1202_CR53","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1016\/j.jacc.2015.09.014","volume":"66","author":"HM Connolly","year":"2015","unstructured":"Connolly HM, Schaff HV, Abel MD, Rubin J, Askew JW, Li Z, Inda JJ, Luis SA, Nishimura RA, Pellikka PA (2015) Early and late outcomes of surgical treatment in carcinoid heart disease. J Am Coll Cardiol 66(20):2189\u20132196. \n                    https:\/\/doi.org\/10.1016\/j.jacc.2015.09.014","journal-title":"J Am Coll Cardiol"},{"issue":"42","key":"1202_CR54","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1093\/eurheartj\/ehv318","volume":"36","author":"Y Adler","year":"2015","unstructured":"Adler Y, Charron P (2015) The 2015 ESC Guidelines on the diagnosis and management of pericardial diseases. Eur Heart J 36(42):2873\u20132874. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehv479","journal-title":"Eur Heart J"},{"issue":"2","key":"1202_CR55","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.pcad.2010.06.003","volume":"53","author":"B Maisch","year":"2010","unstructured":"Maisch B, Ristic A, Pankuweit S (2010) Evaluation and management of pericardial effusion in patients with neoplastic disease. Prog Cardiovasc Dis 53(2):157\u2013163. \n                    https:\/\/doi.org\/10.1016\/j.pcad.2010.06.003","journal-title":"Prog Cardiovasc Dis"},{"issue":"1","key":"1202_CR56","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1001\/jama.1994.03520010071035","volume":"272","author":"PT Vaitkus","year":"1994","unstructured":"Vaitkus PT, Herrmann HC, LeWinter MM (1994) Treatment of malignant pericardial effusion. JAMA 272(1):59\u201364","journal-title":"JAMA"},{"issue":"5","key":"1202_CR57","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/0360-3016(94)00656-6","volume":"31","author":"JR Stewart","year":"1995","unstructured":"Stewart JR, Fajardo LF, Gillette SM, Constine LS (1995) Radiation injury to the heart. Int J Radiat Oncol Biol Phys 31(5):1205\u20131211. \n                    https:\/\/doi.org\/10.1016\/0360-3016(94)00656-6","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"42","key":"1202_CR58","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1093\/eurheartj\/ehv318","volume":"36","author":"Y Adler","year":"2015","unstructured":"Adler Y, Charron P, Imazio M, Badano L, Baron-Esquivias G, Bogaert J, Brucato A, Gueret P, Klingel K, Lionis C, Maisch B, Mayosi B, Pavie A, Ristic AD, Sabate Tenas M, Seferovic P, Swedberg K, Tomkowski W, Achenbach S, Agewall S, Al-Attar N, Angel Ferrer J, Arad M, Asteggiano R, Bueno H, Caforio AL, Carerj S, Ceconi C, Evangelista A, Flachskampf F, Giannakoulas G, Gielen S, Habib G, Kolh P, Lambrinou E, Lancellotti P, Lazaros G, Linhart A, Meurin P, Nieman K, Piepoli MF, Price S, Roos-Hesselink J, Roubille F, Ruschitzka F, Sagrista Sauleda J, Sousa-Uva M, Uwe Voigt J, Luis Zamorano J, European Society of C (2015) 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 36 (42):2921\u20132964. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehv318","journal-title":"Eur Heart J"},{"issue":"3","key":"1202_CR59","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/S0002-9149(00)00937-1","volume":"86","author":"TS Bishiniotis","year":"2000","unstructured":"Bishiniotis TS, Antoniadou S, Katseas G, Mouratidou D, Litos AG, Balamoutsos N (2000) Malignant cardiac tamponade in women with breast cancer treated by pericardiocentesis and intrapericardial administration of triethylenethiophosphoramide (thiotepa). Am J Cardiol 86(3):362\u2013364","journal-title":"Am J Cardiol"},{"issue":"3","key":"1202_CR60","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/sj.bjc.6604866","volume":"100","author":"H Kunitoh","year":"2009","unstructured":"Kunitoh H, Tamura T, Shibata T, Imai M, Nishiwaki Y, Nishio M, Yokoyama A, Watanabe K, Noda K, Saijo N, Jcog Lung Cancer Study Group TJ (2009) A randomised trial of intrapericardial bleomycin for malignant pericardial effusion with lung cancer (JCOG9811). Br J Cancer 100(3):464\u2013469. \n                    https:\/\/doi.org\/10.1038\/sj.bjc.6604866","journal-title":"Br J Cancer"},{"issue":"13","key":"1202_CR61","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1161\/CIRCULATIONAHA.115.018347","volume":"133","author":"J Herrmann","year":"2016","unstructured":"Herrmann J, Yang EH, Iliescu CA, Cilingiroglu M, Charitakis K, Hakeem A, Toutouzas K, Leesar MA, Grines CL, Marmagkiolis K (2016) Vascular toxicities of cancer therapies: the old and the new\u2014an evolving avenue. Circulation 133(13):1272\u20131289. \n                    https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.018347","journal-title":"Circulation"},{"issue":"5","key":"1202_CR62","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1093\/annonc\/mdn713","volume":"20","author":"H Izzedine","year":"2009","unstructured":"Izzedine H, Ederhy S, Goldwasser F, Soria JC, Milano G, Cohen A, Khayat D, Spano JP (2009) Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol 20(5):807\u2013815. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdn713","journal-title":"Ann Oncol"},{"issue":"5","key":"1202_CR63","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.cjca.2014.02.011","volume":"30","author":"HY Small","year":"2014","unstructured":"Small HY, Montezano AC, Rios FJ, Savoia C, Touyz RM (2014) Hypertension due to antiangiogenic cancer therapy with vascular endothelial growth factor inhibitors: understanding and managing a new syndrome. Can J Cardiol 30(5):534\u2013543. \n                    https:\/\/doi.org\/10.1016\/j.cjca.2014.02.011","journal-title":"Can J Cardiol"},{"issue":"3","key":"1202_CR64","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/0165-1110(90)90004-U","volume":"239","author":"ES Hansen","year":"1990","unstructured":"Hansen ES (1990) International Commission for Protection Against Environmental Mutagens and Carcinogens. ICPEMC Working Paper 7\/1\/2. Shared risk factors for cancer and atherosclerosis\u2014a review of the epidemiological evidence. Mutat Res 239(3):163\u2013179","journal-title":"Mutat Res"},{"issue":"30","key":"1202_CR65","doi-asserted-by":"publisher","first-page":"4649","DOI":"10.1200\/JCO.2010.29.9362","volume":"28","author":"HS Haugnes","year":"2010","unstructured":"Haugnes HS, Wethal T, Aass N, Dahl O, Klepp O, Langberg CW, Wilsgaard T, Bremnes RM, Fossa SD (2010) Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J Clin Oncol 28(30):4649\u20134657. \n                    https:\/\/doi.org\/10.1200\/JCO.2010.29.9362","journal-title":"J Clin Oncol"},{"issue":"8","key":"1202_CR66","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1200\/JCO.2000.18.8.1725","volume":"18","author":"MT Meinardi","year":"2000","unstructured":"Meinardi MT, Gietema JA, van der Graaf WT, van Veldhuisen DJ, Runne MA, Sluiter WJ, de Vries EG, Willemse PB, Mulder NH, van den Berg MP, Koops HS, Sleijfer DT (2000) Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 18(8):1725\u20131732","journal-title":"J Clin Oncol"},{"issue":"3","key":"1202_CR67","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/BF00252982","volume":"19","author":"BL Samuels","year":"1987","unstructured":"Samuels BL, Vogelzang NJ, Kennedy BJ (1987) Severe vascular toxicity associated with vinblastine, bleomycin, and cisplatin chemotherapy. Cancer Chemother Pharmacol 19(3):253\u2013256","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"1202_CR68","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.jjcc.2009.03.009","volume":"54","author":"Y Arima","year":"2009","unstructured":"Arima Y, Oshima S, Noda K, Fukushima H, Taniguchi I, Nakamura S, Shono M, Ogawa H (2009) Sorafenib-induced acute myocardial infarction due to coronary artery spasm. J Cardiol 54(3):512\u2013515. \n                    https:\/\/doi.org\/10.1016\/j.jjcc.2009.03.009","journal-title":"J Cardiol"},{"issue":"6","key":"1202_CR69","doi-asserted-by":"publisher","first-page":"E94","DOI":"10.1002\/clc.20291","volume":"32","author":"G Gemici","year":"2009","unstructured":"Gemici G, Cincin A, Degertekin M, Oktay A (2009) Paclitaxel-induced ST-segment elevations. Clin Cardiol 32(6):E94\u2013E96. \n                    https:\/\/doi.org\/10.1002\/clc.20291","journal-title":"Clin Cardiol"},{"issue":"3","key":"1202_CR70","doi-asserted-by":"publisher","first-page":"442","DOI":"10.4103\/0973-1482.103530","volume":"8","author":"K Shah","year":"2012","unstructured":"Shah K, Gupta S, Ghosh J, Bajpai J, Maheshwari A (2012) Acute non-ST elevation myocardial infarction following paclitaxel administration for ovarian carcinoma: a case report and review of literature. J Cancer Res Ther 8(3):442\u2013444. \n                    https:\/\/doi.org\/10.4103\/0973-1482.103530","journal-title":"J Cancer Res Ther"},{"issue":"26","key":"1202_CR71","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1056\/NEJMc1305687","volume":"368","author":"SC Darby","year":"2013","unstructured":"Darby SC, Ewertz M, Hall P (2013) Ischemic heart disease after breast cancer radiotherapy. N Engl J Med 368(26):2527. \n                    https:\/\/doi.org\/10.1056\/NEJMc1304601","journal-title":"N Engl J Med"},{"issue":"6","key":"1202_CR72","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1182\/blood-2010-04-278796","volume":"117","author":"SM Castellino","year":"2011","unstructured":"Castellino SM, Geiger AM, Mertens AC, Leisenring WM, Tooze JA, Goodman P, Stovall M, Robison LL, Hudson MM (2011) Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. Blood 117(6):1806\u20131816. \n                    https:\/\/doi.org\/10.1182\/blood-2010-04-278796","journal-title":"Blood"},{"issue":"3","key":"1202_CR73","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1093\/jnci\/djk029","volume":"99","author":"AJ Swerdlow","year":"2007","unstructured":"Swerdlow AJ, Higgins CD, Smith P, Cunningham D, Hancock BW, Horwich A, Hoskin PJ, Lister A, Radford JA, Rohatiner AZ, Linch DC (2007) Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst 99(3):206\u2013214. \n                    https:\/\/doi.org\/10.1093\/jnci\/djk029","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"1202_CR74","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.jvs.2003.08.031","volume":"39","author":"SW Cheng","year":"2004","unstructured":"Cheng SW, Ting AC, Ho P, Wu LL (2004) Accelerated progression of carotid stenosis in patients with previous external neck irradiation. J Vasc Surg 39(2):409\u2013415. \n                    https:\/\/doi.org\/10.1016\/j.jvs.2003.08.031","journal-title":"J Vasc Surg"},{"key":"1202_CR75","unstructured":"AWMF (Stand: 08.08.2012) S3-Leitlinie zur Diagnostik, Therapie und Nachsorge der extracraniellen Carotisstenose"},{"issue":"3","key":"1202_CR76","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.jvs.2010.09.056","volume":"53","author":"T Tallarita","year":"2011","unstructured":"Tallarita T, Oderich GS, Lanzino G, Cloft H, Kallmes D, Bower TC, Duncan AA, Gloviczki P (2011) Outcomes of carotid artery stenting versus historical surgical controls for radiation-induced carotid stenosis. J Vasc Surg 53(3):629\u2013636. \n                    https:\/\/doi.org\/10.1016\/j.jvs.2010.09.056\n                    \n                   (e621\u2013625)","journal-title":"J Vasc Surg"},{"issue":"1","key":"1202_CR77","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","volume":"37","author":"N Galie","year":"2016","unstructured":"Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M, Aboyans V, Vaz Carneiro A, Achenbach S, Agewall S, Allanore Y, Asteggiano R, Paolo Badano L, Albert Barbera J, Bouvaist H, Bueno H, Byrne RA, Carerj S, Castro G, Erol C, Falk V, Funck-Brentano C, Gorenflo M, Granton J, Iung B, Kiely DG, Kirchhof P, Kjellstrom B, Landmesser U, Lekakis J, Lionis C, Lip GY, Orfanos SE, Park MH, Piepoli MF, Ponikowski P, Revel MP, Rigau D, Rosenkranz S, Voller H, Luis Zamorano J (2016) 2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 37(1):67\u2013119. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehv317","journal-title":"Eur Heart J"},{"issue":"2","key":"1202_CR78","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s40264-014-0258-4","volume":"38","author":"J Tamargo","year":"2015","unstructured":"Tamargo J, Caballero R, Delpon E (2015) Cancer chemotherapy and cardiac arrhythmias: a review. Drug Saf 38(2):129\u2013152. \n                    https:\/\/doi.org\/10.1007\/s40264-014-0258-4","journal-title":"Drug Saf"},{"issue":"6","key":"1202_CR79","doi-asserted-by":"publisher","first-page":"5212","DOI":"10.1016\/j.ijcard.2013.08.033","volume":"168","author":"W Jurczak","year":"2013","unstructured":"Jurczak W, Szmit S, Sobocinski M, Machaczka M, Drozd-Sokolowska J, Joks M, Dzietczenia J, Wrobel T, Kumiega B, Zaucha JM, Knopinska-Posluszny W, Spychalowicz W, Prochwicz A, Drohomirecka A, Skotnicki AB (2013) Premature cardiovascular mortality in lymphoma patients treated with (R)-CHOP regimen\u2014a national multicenter study. Int J Cardiol 168(6):5212\u20135217. \n                    https:\/\/doi.org\/10.1016\/j.ijcard.2013.08.033","journal-title":"Int J Cardiol"},{"issue":"3","key":"1202_CR80","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1097\/01.smj.0000257382.89910.fe","volume":"100","author":"S Kilickap","year":"2007","unstructured":"Kilickap S, Barista I, Akgul E, Aytemir K, Aksoy S, Tekuzman G (2007) Early and late arrhythmogenic effects of doxorubicin. South Med J 100(3):262\u2013265. \n                    https:\/\/doi.org\/10.1097\/01.smj.0000257382.89910.fe","journal-title":"South Med J"},{"key":"1202_CR81","unstructured":"Arbuck SG, Strauss H, Rowinsky E, Christian M, Suffness M, Adams J, Oakes M, McGuire W, Reed E, Gibbs H et al. (1993) A reassessment of cardiac toxicity associated with Taxol. J Natl Cancer Inst Monogr (15):117\u2013130"},{"issue":"2","key":"1202_CR82","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/sj.bmt.1702106","volume":"25","author":"M Ando","year":"2000","unstructured":"Ando M, Yokozawa T, Sawada J, Takaue Y, Togitani K, Kawahigashi N, Narabayashi M, Takeyama K, Tanosaki R, Mineishi S, Kobayashi Y, Watanabe T, Adachi I, Tobinai K (2000) Cardiac conduction abnormalities in patients with breast cancer undergoing high-dose chemotherapy and stem cell transplantation. Bone Marrow Transplant 25(2):185\u2013189. \n                    https:\/\/doi.org\/10.1038\/sj.bmt.1702106","journal-title":"Bone Marrow Transplant"},{"issue":"19","key":"1202_CR83","doi-asserted-by":"publisher","first-page":"3609","DOI":"10.1200\/JCO.2003.10.009","volume":"21","author":"JT Barbey","year":"2003","unstructured":"Barbey JT, Pezzullo JC, Soignet SL (2003) Effect of arsenic trioxide on QT interval in patients with advanced malignancies. J Clin Oncol 21(19):3609\u20133615. \n                    https:\/\/doi.org\/10.1200\/JCO.2003.10.009","journal-title":"J Clin Oncol"},{"issue":"2","key":"1202_CR84","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1182\/blood.V98.2.266","volume":"98","author":"P Westervelt","year":"2001","unstructured":"Westervelt P, Brown RA, Adkins DR, Khoury H, Curtin P, Hurd D, Luger SM, Ma MK, Ley TJ, DiPersio JF (2001) Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. Blood 98(2):266\u2013271","journal-title":"Blood"},{"issue":"24","key":"1202_CR85","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa055104","volume":"354","author":"H Kantarjian","year":"2006","unstructured":"Kantarjian H, Giles F, Wunderle L, Bhalla K, O\u2019Brien S, Wassmann B, Tanaka C, Manley P, Rae P, Mietlowski W, Bochinski K, Hochhaus A, Griffin JD, Hoelzer D, Albitar M, Dugan M, Cortes J, Alland L, Ottmann OG (2006) Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354(24):2542\u20132551. \n                    https:\/\/doi.org\/10.1056\/NEJMoa055104","journal-title":"N Engl J Med"},{"issue":"1","key":"1202_CR86","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/0002-9149(92)91393-I","volume":"70","author":"RL Larsen","year":"1992","unstructured":"Larsen RL, Jakacki RI, Vetter VL, Meadows AT, Silber JH, Barber G (1992) Electrocardiographic changes and arrhythmias after cancer therapy in children and young adults. Am J Cardiol 70(1):73\u201377","journal-title":"Am J Cardiol"},{"issue":"23","key":"1202_CR87","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1016\/j.jacc.2013.01.090","volume":"61","author":"C Jaworski","year":"2013","unstructured":"Jaworski C, Mariani JA, Wheeler G, Kaye DM (2013) Cardiac complications of thoracic irradiation. J Am Coll Cardiol 61(23):2319\u20132328. \n                    https:\/\/doi.org\/10.1016\/j.jacc.2013.01.090","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"1202_CR88","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1002\/ejhf.670","volume":"18","author":"MS Anker","year":"2016","unstructured":"Anker MS, Ebner N, Hildebrandt B, Springer J, Sinn M, Riess H, Anker SD, Landmesser U, Haverkamp W, von Haehling S (2016) Resting heart rate is an independent predictor of death in patients with colorectal, pancreatic, and non-small cell lung cancer: results of a prospective cardiovascular long-term study. Eur J Heart Fail 18(12):1524\u20131534. \n                    https:\/\/doi.org\/10.1002\/ejhf.670","journal-title":"Eur J Heart Fail"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00392-018-1202-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-018-1202-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-018-1202-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,16]],"date-time":"2019-02-16T22:15:24Z","timestamp":1550355324000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00392-018-1202-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,16]]},"references-count":88,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["1202"],"URL":"https:\/\/doi.org\/10.1007\/s00392-018-1202-x","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,16]]},"assertion":[{"value":"12 September 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}